Key result
Transsubclavian TAVR successfully treats severe AS in a kidney transplant recipient, reducing mean gradient ~81%.
Why the study?
Transfemoral TAVR is the gold standard but is not feasible in a considerable number of patients, including kidney transplant recipients with severe AS.
Does transsubclavian TAVR improve valve hemodynamics in a patient with severe aortic stenosis and prior kidney transplantation?
Case Report (n=1)
No
Does transsubclavian TAVR improve valve hemodynamics in a patient with severe aortic stenosis and prior kidney transplantation?
Transsubclavian TAVR is a feasible and effective alternative for patients with severe aortic stenosis who are ineligible for transfemoral access due to prior kidney transplantation.
Hypothesis-generating for TS-TAVR in kidney transplant recipients ineligible for transfemoral access; prospective studies needed.
RATIONALE: Although the transfemoral approach is the gold standard for transcatheter aortic valve replacement (TAVR), it is not feasible in a considerable number of patients. We report a case of successful transsubclavian TAVR (TS-TAVR) in a patient with severe aortic stenosis (AS) who was ineligible for transfemoral TAVR because she was a kidney transplant recipient. PATIENT CONCERNS: A 72-year-old Korean woman, who had previously undergone kidney transplantation in the right iliac fossa for end-stage kidney disease, was admitted to our center with dyspnea. Upon auscultation, grade IV systolic murmurs were detected in both upper sternal borders and the left lower sternal border, suggestive of valvular heart disease. DIAGNOSIS: Two-dimensional transthoracic echocardiography revealed heavy calcification of the aortic valve with a high peak velocity (4.54 m/s) and mean pressure gradient (48.49 mm Hg), indicative of severe AS. INTERVENTIONS: TS-TAVR was performed by a heart team comprised of interventional cardiologists, cardiac surgeons, and anesthesiologists. A self-expandable valve prosthesis (CoreValveTM Evolut RTM, Medtronic Inc., Minneapolis, MN) was successfully deployed via the left subclavian artery. OUTCOMES: Post-TAVR 2-dimensional transthoracic echocardiography demonstrated a well-functioning valve with mild paravalvular leakage. The peak velocity had declined from 4.54 m/s to 2.22 to 2.24 m/s, and the mean pressure gradient had declined from 48.49 to 8.57-9.61 mmHg. The patient was discharged successfully and uneventfully. LESSONS: Because kidney transplant recipients with severe AS are considered poor candidates for transfemoral TAVR, TS-TAVR is a suitable alternative to consider.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2021) conducted a case report in Severe aortic stenosis (n=1). Transsubclavian transcatheter aortic valve replacement (TS-TAVR) was evaluated on Hemodynamic improvement (peak velocity and mean pressure gradient). Transsubclavian transcatheter aortic valve replacement successfully treated severe aortic stenosis in a kidney transplant recipient, reducing the mean pressure gradient from 48.49 to 8.57-9.61 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: